Cofactor Genomics

Cofactor Genomics builds RNA-based diagnostics using what it calls Predictive Immune Modeling: multidimensional RNA expression models of the tumour immune microenvironment trained on large datasets. Its OncoPrism assay is intended to predict response to checkpoint inhibitors, with validation work presented in head and neck and other solid tumours and analytical validation published in molecular diagnostics journals. The company is CAP and CLIA accredited and, per its YC profile, is backed by Menlo Ventures, DCVC and Ascension Ventures. Evidence is at the clinical validation stage rather than randomised proof of benefit.